OBJECTIVE A relationship between the serotoninergic and the opiatergic system in the
pathogenesis of head pain is supported by several data. This study was carried out to …

We evaluated the sensitivity of 5-HT1D receptors in patients with migraine using sumatriptan
as a pharmacological probe. The drug inhibits the release of ACTH, cortisol and prolactin …

The purpose of this study was to assess the sensitivity of 5-HT1D receptors in migraine
using sumatriptan as a pharmacological probe. The drug stimulates the release of growth …

Objective.—To assess the sensitivity of 5‐HT1D receptors in chronic tension‐type headache
using sumatriptan as a pharmacological probe. Background.—Previous studies have …

Sumatriptan, a new antimigraine drug with high affinity and selectivity for certain 5-
hydroxytryptamine (5-HT1D) receptor subtypes, was administered to 12 normal subjects, in …

The neuroendocrine effects of the 5-HT receptor agonist, sumatriptan (6 mg
subcutaneously), were studied in 11 healthy male subjects using a placebo-controlled, cross …

Objective.—To investigate the response to sumatriptan in migraineurs with unilateral cranial
autonomic symptoms such as lacrimation, eye redness, eyelid edema, nasal congestion …

At present, four main types of serotonin (5-HT) receptors have been identified in the brain (5-
HT1, 5-HT2, 5-HT3, and 5-HT4). In addition, the 5-HT1 have been further subclassified. We …

Background. Sumatriptan, a specific agonist at 5-HT1D receptors, stimulates release of
growth hormone (GH) and inhibits release of prolactin (PRL). Methods. We gave sumatriptan …

The anatomical distribution of [3H] sumatriptan-binding sites was analysed in brain tissue
sections from 11 subjects. Relevant concentrations of [3H] sumatriptan-binding sites were …